Michelle Vuolo is the Head of Quality at Tulip Interfaces, Inc., a platform developer that allows manufacturers of many industries to build digital content to manage their operations. Before joining Tulip, Michelle spent over 24 years in the biopharmaceutical and medical devices industries in quality control laboratories, engineering technical support, quality assurance management, and computerized systems compliance. Michelle has a strong understanding of the needs of the life sciences industry and is motivated to evolve stagnant ways of meeting compliance requirements, especially as it relates to the 4.0 world. She joined ISPE in 2008.
Co-Lead Validation 4.0 Working Group
Member of the ISPE Pharma 4.0 Steering Committee
Pharmaceutical manufacturing’s digital transformation is constrained not by a lack of data, but by decision velocity: the speed, quality, and auditability of translating operational signals into compliant actions.
The pharmaceutical industry stands at the precipice of a revolution as emerging digital technologies provide new opportunities to boost productivity through continuous process improvements. The Pharma 4.0™ framework, an adaptation of the broader Industry 4.0 movement, aims to transform how drugs are produced and delivered.
We will show how continuous, real-time capturing of data with immediate data analysis by an ML algorithm can improve control over a critical quality attribute. The ML-analyzed data provides the evidence for validation of the change by demonstrating more control over the process along with a decrease in process risks.
A fundamental GMP requirement is that processes, systems, and methods used to produce medicines and treatments are validated, meaning their fitness for a purpose is demonstrated. If Industry 4.0 is to succeed in the pharma space as